ALL: Acute lymphoblastic leukemia; AML: Acute myelocytic leukemia; BCP- ALL: B-cell precursor acute lymphoblastic leukemia; BLK: B lymphocyte kinase; BTK: Bruton ’ s tyrosine

leukemia; pre T-LBL, precursor T-cell lymphoblastic leukemia/lymphoma; AML, acute myeloid leukemia; DLBCL, diffuse large B-cell lymphoma; ALL, acute lymphocytic leukemia; T-ALL,

IKZF1 gene defects are associated with inferior treatment outcome in both childhood and adult B-cell precursor acute lymphoblastic leukemia and occur in more than 70% of

T cell receptor delta gene recombinatorial events were found in 91% of acute T cell lymphoblastic leukemia, 68% of non-T, non-B lymphoid precursor acute.. lymphoblastic leukemia

ALL: Acute lymphoblastic leukemia; T-ALL: T-cell acute lymphoblastic leukemia; B-ALL: B-cell acute lymphoblastic leukemia; MRD: Minimal residual disease; PR: Prednisone response;

Precursor T-cell lymphoblastic leukemia; T-cell acute lymphoblastic leukemia; T-cell ALL; T-ALL; T-cell receptor; thymocyte; transcription factor.. Clinics

Application of Mathematical Logic for Cytogenetic Definition and Risk Stratification of B-Cell Precursor Acute Lymphoblastic Leukemia

positive precursor B-cell acute lymphoblastic leukemia with positive minimal residual disease (0.32%) before conditioning treatment for hematopoietic stem cell transplantation?.

BCP-ALL: B-cell precursor acute lymphoblastic leukemia; CML: Chronic myeloid leukemia; HeH: High hyperdiploidy; FISH: Fluorescence in situ hybridization; mFISH: Multicolor FISH;

van Leeuwen (2017) Tumor suppressors BTG1 and IKZF1 cooperate during mouse leukemia development and increase relapse risk in B cell precursor acute lymphoblastic leukemia

Blinatumomab, a bispecific T-cell engager monoclonal antibody used to manage Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia

ACAs: Additional cytogenetic abnormalities; ALL: Acute lymphoblastic leukemia; aMCB: Array-proven high-resolution multicolor banding; B-ALL: B cell acute lymphoblastic leukemia;

ruxolitinib on the viability of PDX cells with JAK2 translocations in mono-culture, or in co-culture with primary MSCs. Mean±SEM of three JAK2 translocated samples is shown.

We aimed at the detection of recently identified tyrosine kinase fusion genes in 153 B-other cases of a population-based cohort of 574 Dutch/German pediatric BCP-ALL patients at

Abbreviations: T/M-MPAL, T-lymphoid/myeloid mixed phenotype acute leukemia; ETP-ALL, early T-cell precursor acute lymphoblastic leukemia; AML-M0, minimally differentiated acute

altered phenotypes on neutrophil lineage cells, but not on other relevant hematopoietic cell compartments (e.g. maturing monocytes and NRBC) which might also be abnormal,

ALL: Acute lymphoblastic leukemia; AML: Acute myeloid leukemia; BAFF: B cell-activating factor; BCMA: B cell maturation antigen; BiKE: Bispecific NK cell engager; BiTE: Bispecific

ERG+, aberrant ERG expression; AML, acute myeloid leukemia; T-ALL, T lymphoblastic leukemia; B-ALL, B lymphoblastic leukemia; DLBCL, diffuse large B-cell lymphoma; TMA,